Evidence map›Paper›PMID 41737560›Full record

ArticleFrontiers in pharmacology2026

Crocin protects against smoke-induced chronic obstructive pulmonary disease by regulating AKT1.

Yuehong Zhu, Yuntao Jiang, Jieping Xu, Sicheng Yan, Zhihong Ma

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuehong Zhu *Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Yuntao Jiang *Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Jieping Xu *Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Sicheng YanHuzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Zhihong MaHuzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disorder characterized by persistent airflow limitation and pathological features such as airway remodeling. Identifying molecular targets involved in airway epithelial dysfunction is crucial for developing COPD therapies. Crocin, a carotenoid glycoside from saffron ( Methods: We first employed predictive strategies, including network analysis, to identify common targets of crocin and COPD. Protein-protein interaction (PPI) networks were constructed, and core targets were screened via topology analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict signaling pathways. Molecular docking and dynamics simulations were then used to assess the binding potential between crocin and the core targets. Finally, the function of crocin against COPD was evaluated using the Cellular Thermal Shift Assay (CETSA) Results: Network analysis predicted 243 common targets, from which 48 candidate targets were identified. GO and KEGG enrichment analyses suggested the PI3K-AKT signaling pathway as a potentially key mechanism. Among the top-ranked core targets, molecular docking indicated favorable binding energies between crocin and proteins such as ALB and AKT1, a finding further corroborated by molecular dynamics simulations. Subsequent CETSA suggested a direct interaction between crocin and AKT1. Conclusion: These findings support the therapeutic potential of crocin in COPD through its anti-inflammatory activity and regulation of AKT1. Despite potential PAINS properties, the consistency across network,

Indexed as

anti-inflammationCOPDcrocinmolecular dynamicsmulti-targetnetwork analysisPi3k-akt

Identifiers

PMID41737560
PMCPMC12926455

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.